bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S2 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells
Authors: Calvo Veronica , Zheng Wei , Adam-Artigues Anna , Staschke Kirk A. , Huang Xin , Cheung Julie F. , Nobre Ana Rita , Fujisawa Sho , Liu David , Fumagalli Maria , Surguladze David , Stokes Michael E. , Nowacek Ari , Mulvihill Mark , Farias Eduardo F. , Aguirre-Ghiso Julio A.
Published: December 2023

Supplementary Table 2: Enzymatic and cell based IC50 values related to PERK, ATF4 and GCN2
Supplementary Figure S6 from OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
Authors: Buckley David N. , Lewinger Juan Pablo , Gooden Gerald , Spillman Monique , Neuman Monica , Guo X. Mona , Tew Ben Yi , Miller Heather , Khetan Varun U. , Shulman Lee P. , Roman Lynda , Salhia Bodour
Published: December 2023

Figure S6: Clustering of tissue from MC samples
Supplementary Figure S4 from OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
Authors: Buckley David N. , Lewinger Juan Pablo , Gooden Gerald , Spillman Monique , Neuman Monica , Guo X. Mona , Tew Ben Yi , Miller Heather , Khetan Varun U. , Shulman Lee P. , Roman Lynda , Salhia Bodour
Published: December 2023

Figure S4: UMAP analysis showing distribution by age, race and sample source
Supplementary Figure S2 from OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
Authors: Buckley David N. , Lewinger Juan Pablo , Gooden Gerald , Spillman Monique , Neuman Monica , Guo X. Mona , Tew Ben Yi , Miller Heather , Khetan Varun U. , Shulman Lee P. , Roman Lynda , Salhia Bodour
Published: December 2023

Figure S2: Hybrid probe capture sequencing metrics
Supplementary Figure S1 from OvaPrint—A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer
Authors: Buckley David N. , Lewinger Juan Pablo , Gooden Gerald , Spillman Monique , Neuman Monica , Guo X. Mona , Tew Ben Yi , Miller Heather , Khetan Varun U. , Shulman Lee P. , Roman Lynda , Salhia Bodour
Published: December 2023

Figure S1: Repeated cross validation with nested resampling diagram
Supplementary Table 2 from Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment
Authors: Wrenn Emma D. , Apfelbaum April A. , Rudzinski Erin R. , Deng Xuemei , Jiang Wei , Sud Sudha , Van Noord Raelene A. , Newman Erika A. , Garcia Nicolas M. , Miyaki Aya , Hoglund Virginia J. , Bhise Shruti S. , Kanaan Sami B. , Waltner Olivia G. , Furlan Scott N. , Lawlor Elizabeth R.
Published: December 2023

Supplemental Table 2. 52 genes overlapping between markers of cells with high GO:BP Mesenchymal Development from A673 and CHLA10 single cell sequencing and EWS::FLI1 repressed gene set.
Supplemental Table 3 from Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment
Authors: Wrenn Emma D. , Apfelbaum April A. , Rudzinski Erin R. , Deng Xuemei , Jiang Wei , Sud Sudha , Van Noord Raelene A. , Newman Erika A. , Garcia Nicolas M. , Miyaki Aya , Hoglund Virginia J. , Bhise Shruti S. , Kanaan Sami B. , Waltner Olivia G. , Furlan Scott N. , Lawlor Elizabeth R.
Published: December 2023

Supplemental Table 3. RNAseq-derived gene expression data for CD73- and CD73+ A673 and CHLA10 cells.
Supplementary Table S4 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Authors: Kamran Sophia C. , Zhou Yuzhen , Otani Keisuke , Drumm Michael , Otani Yukako , Wu Shulin , Wu Chin-Lee , Feldman Adam S. , Wszolek Matthew , Lee Richard J. , Saylor Philip J. , Lennerz Jochen , Van Allen Eliezer , Willers Henning , Hong Theodore S. , Liu Yang , Davicioni Elai , Gibb Ewan A. , Shipley William U. , Mouw Kent W. , Efstathiou Jason A. , Miyamoto David T.
Published: December 2023

Details of DDR gene mutations identified in bladder TMT cohort
Supplemental Figure S2 from Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment
Authors: Wrenn Emma D. , Apfelbaum April A. , Rudzinski Erin R. , Deng Xuemei , Jiang Wei , Sud Sudha , Van Noord Raelene A. , Newman Erika A. , Garcia Nicolas M. , Miyaki Aya , Hoglund Virginia J. , Bhise Shruti S. , Kanaan Sami B. , Waltner Olivia G. , Furlan Scott N. , Lawlor Elizabeth R.
Published: December 2023

Supplemental Figure S2. CD73+ cells are enriched in EMT and ECM gene expression. Related to Figure 2.
Supplementary Table S5 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
Authors: Koch Raphael , Haveman Lianne , Ladenstein Ruth , Brichard Benedicte , Jürgens Heribert , Cyprova Sona , van den Berg Henk , Hassenpflug Wolf , Raciborska Anna , Ek Torben , Baumhoer Daniel , Egerer Gerlinde , Kager Leo , Renard Marleen , Hauser Peter , Burdach Stefan , Bovee Judith V.M.G. , Hong Angela M. , Reichardt Peter , Kruseova Jarmila , Streitbürger Arne , Kühne Thomas , Kessler Torsten , Bernkopf Marie , Butterfaß-Bahloul Trude , Dhooge Catharina , Bauer Sebastian , Kiss János , Paulussen Michael , Bonar Fiona , Ranft Andreas , Timmermann Beate , Rascon Jelena , Vieth Volker , Kanerva Jukka , Faldum Andreas , Hartmann Wolfgang , Hjorth Lars , Bhadri Vivek A. , Metzler Markus , Gelderblom Hans , Dirksen Uta
Published: December 2023

List of patients who died from a cause other than cancer (N=2)
Supplementary Figure S4 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Authors: Kamran Sophia C. , Zhou Yuzhen , Otani Keisuke , Drumm Michael , Otani Yukako , Wu Shulin , Wu Chin-Lee , Feldman Adam S. , Wszolek Matthew , Lee Richard J. , Saylor Philip J. , Lennerz Jochen , Van Allen Eliezer , Willers Henning , Hong Theodore S. , Liu Yang , Davicioni Elai , Gibb Ewan A. , Shipley William U. , Mouw Kent W. , Efstathiou Jason A. , Miyamoto David T.
Published: December 2023

Comparison of TCGA subtypes between our cohort and the TCGA Bladder cohort.
Supplementary Table S2 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
Authors: Koch Raphael , Haveman Lianne , Ladenstein Ruth , Brichard Benedicte , Jürgens Heribert , Cyprova Sona , van den Berg Henk , Hassenpflug Wolf , Raciborska Anna , Ek Torben , Baumhoer Daniel , Egerer Gerlinde , Kager Leo , Renard Marleen , Hauser Peter , Burdach Stefan , Bovee Judith V.M.G. , Hong Angela M. , Reichardt Peter , Kruseova Jarmila , Streitbürger Arne , Kühne Thomas , Kessler Torsten , Bernkopf Marie , Butterfaß-Bahloul Trude , Dhooge Catharina , Bauer Sebastian , Kiss János , Paulussen Michael , Bonar Fiona , Ranft Andreas , Timmermann Beate , Rascon Jelena , Vieth Volker , Kanerva Jukka , Faldum Andreas , Hartmann Wolfgang , Hjorth Lars , Bhadri Vivek A. , Metzler Markus , Gelderblom Hans , Dirksen Uta
Published: December 2023

Characteristics of patients who were eligible but not randomized or who were randomized
Supplementary Figure S15 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Authors: Kamran Sophia C. , Zhou Yuzhen , Otani Keisuke , Drumm Michael , Otani Yukako , Wu Shulin , Wu Chin-Lee , Feldman Adam S. , Wszolek Matthew , Lee Richard J. , Saylor Philip J. , Lennerz Jochen , Van Allen Eliezer , Willers Henning , Hong Theodore S. , Liu Yang , Davicioni Elai , Gibb Ewan A. , Shipley William U. , Mouw Kent W. , Efstathiou Jason A. , Miyamoto David T.
Published: December 2023

GSC Subtype Signatures by ERCC2 mutation.
Supplementary Figure S1 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Authors: Kamran Sophia C. , Zhou Yuzhen , Otani Keisuke , Drumm Michael , Otani Yukako , Wu Shulin , Wu Chin-Lee , Feldman Adam S. , Wszolek Matthew , Lee Richard J. , Saylor Philip J. , Lennerz Jochen , Van Allen Eliezer , Willers Henning , Hong Theodore S. , Liu Yang , Davicioni Elai , Gibb Ewan A. , Shipley William U. , Mouw Kent W. , Efstathiou Jason A. , Miyamoto David T.
Published: December 2023

Sample inclusion and analytic workflow.
Study Protocol S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
Authors: Koch Raphael , Haveman Lianne , Ladenstein Ruth , Brichard Benedicte , Jürgens Heribert , Cyprova Sona , van den Berg Henk , Hassenpflug Wolf , Raciborska Anna , Ek Torben , Baumhoer Daniel , Egerer Gerlinde , Kager Leo , Renard Marleen , Hauser Peter , Burdach Stefan , Bovee Judith V.M.G. , Hong Angela M. , Reichardt Peter , Kruseova Jarmila , Streitbürger Arne , Kühne Thomas , Kessler Torsten , Bernkopf Marie , Butterfaß-Bahloul Trude , Dhooge Catharina , Bauer Sebastian , Kiss János , Paulussen Michael , Bonar Fiona , Ranft Andreas , Timmermann Beate , Rascon Jelena , Vieth Volker , Kanerva Jukka , Faldum Andreas , Hartmann Wolfgang , Hjorth Lars , Bhadri Vivek A. , Metzler Markus , Gelderblom Hans , Dirksen Uta
Published: December 2023

Study protocol of all parts of the EWING 2008 trial
Supplementary Table S7 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
Authors: Kawai Akira , Ishihara Mikiya , Nakamura Tomoki , Kitano Shigehisa , Iwata Shintaro , Takada Kohichi , Emori Makoto , Kato Koji , Endo Makoto , Matsumoto Yoshihiro , Kakunaga Shigeki , Sato Eiichi , Miyahara Yoshihiro , Morino Kunihiko , Tanaka Shinya , Takahashi Shuichi , Matsuo Fujio , Matsumine Akihiko , Kageyama Shinichi , Ueda Takafumi
Published: December 2023

Summary of cytokine release syndrome characteristics for individual patients
Supplementary Table S4 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
Authors: Nawrocki Steffan T. , Olea Julian , Villa Celi Claudia , Dadrastoussi Homa , Wu Kaijin , Tsao-Wei Denice , Colombo Anthony , Coffey Matt , Fernandez Hernandez Eduardo , Chen Xuelian , Nuovo Gerard J. , Carew Jennifer S. , Mohrbacher Ann F. , Fields Paul , Kuhn Peter , Siddiqi Imran , Merchant Akil , Kelly Kevin R.
Published: December 2023

Supplementary Table 4. Distance from tumor cell to immune cell for each patient (Figure 5C)
Supplementary Table S5 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
Authors: Kawai Akira , Ishihara Mikiya , Nakamura Tomoki , Kitano Shigehisa , Iwata Shintaro , Takada Kohichi , Emori Makoto , Kato Koji , Endo Makoto , Matsumoto Yoshihiro , Kakunaga Shigeki , Sato Eiichi , Miyahara Yoshihiro , Morino Kunihiko , Tanaka Shinya , Takahashi Shuichi , Matsuo Fujio , Matsumine Akihiko , Kageyama Shinichi , Ueda Takafumi
Published: December 2023

List of prior treatment drugs
Supplementary Figure S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
Authors: Nawrocki Steffan T. , Olea Julian , Villa Celi Claudia , Dadrastoussi Homa , Wu Kaijin , Tsao-Wei Denice , Colombo Anthony , Coffey Matt , Fernandez Hernandez Eduardo , Chen Xuelian , Nuovo Gerard J. , Carew Jennifer S. , Mohrbacher Ann F. , Fields Paul , Kuhn Peter , Siddiqi Imran , Merchant Akil , Kelly Kevin R.
Published: December 2023

Supplementary Figure 1. Induced expression of cytokines, CD69 in lymphocytes, and PD-L1 in MM cells with no changes in T cell clonality
Supplementary Table S8 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
Authors: Conte Benedetta , Boni Luca , Bisagni Giancarlo , Durando Antonio , Sanna Giovanni , Gori Stefania , Garrone Ornella , Tamberi Stefano , De Placido Sabino , Schettini Francesco , Pazzola Antonio , Ponzone Riccardo , Montemurro Filippo , Lunardi Gianluigi , Notaro Rosario , De Angioletti Maria , Turletti Anna , Mansutti Mauro , Puglisi Fabio , Frassoldati Antonio , Porpiglia Mauro , Fabi Alessandra , Generali Daniele , Scognamiglio Giovanni , Rossi Maura , Brasó-Maristany Fara , Prat Aleix , Cardinali Barbara , Piccioli Patrizia , Serra Martina , Lastraioli Sonia , Bighin Claudia , Poggio Francesca , Lambertini Matteo , Del Mastro Lucia
Published: December 2023

Univariate analyses for DFS, OS and metastasis
Supplementary Table S4 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
Authors: Okuma Hitomi S. , Watanabe Keisuke , Tsuchihashi Kenji , Machida Ryunosuke , Sadachi Ryo , Hirakawa Akihiro , Ariyama Hiroshi , Kanai Masashi , Kamikura Masahisa , Anjo Kenta , Hiramitsu Akari , Sekine Shigeki , Okita Natsuko , Mano Hiroyuki , Nishikawa Hiroyoshi , Nakamura Kenichi , Yonemori Kan
Published: December 2023

Supplementary Table S4: Representativeness of Study Participants
Supplementary Table S6 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
Authors: Conte Benedetta , Boni Luca , Bisagni Giancarlo , Durando Antonio , Sanna Giovanni , Gori Stefania , Garrone Ornella , Tamberi Stefano , De Placido Sabino , Schettini Francesco , Pazzola Antonio , Ponzone Riccardo , Montemurro Filippo , Lunardi Gianluigi , Notaro Rosario , De Angioletti Maria , Turletti Anna , Mansutti Mauro , Puglisi Fabio , Frassoldati Antonio , Porpiglia Mauro , Fabi Alessandra , Generali Daniele , Scognamiglio Giovanni , Rossi Maura , Brasó-Maristany Fara , Prat Aleix , Cardinali Barbara , Piccioli Patrizia , Serra Martina , Lastraioli Sonia , Bighin Claudia , Poggio Francesca , Lambertini Matteo , Del Mastro Lucia
Published: December 2023

Patients’ characteristics SNP rs749292
Supplementary Table S5 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
Authors: Conte Benedetta , Boni Luca , Bisagni Giancarlo , Durando Antonio , Sanna Giovanni , Gori Stefania , Garrone Ornella , Tamberi Stefano , De Placido Sabino , Schettini Francesco , Pazzola Antonio , Ponzone Riccardo , Montemurro Filippo , Lunardi Gianluigi , Notaro Rosario , De Angioletti Maria , Turletti Anna , Mansutti Mauro , Puglisi Fabio , Frassoldati Antonio , Porpiglia Mauro , Fabi Alessandra , Generali Daniele , Scognamiglio Giovanni , Rossi Maura , Brasó-Maristany Fara , Prat Aleix , Cardinali Barbara , Piccioli Patrizia , Serra Martina , Lastraioli Sonia , Bighin Claudia , Poggio Francesca , Lambertini Matteo , Del Mastro Lucia
Published: December 2023

Patients’ characteristics SNP rs10046
Supplementary Figure S6 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
Authors: Okuma Hitomi S. , Watanabe Keisuke , Tsuchihashi Kenji , Machida Ryunosuke , Sadachi Ryo , Hirakawa Akihiro , Ariyama Hiroshi , Kanai Masashi , Kamikura Masahisa , Anjo Kenta , Hiramitsu Akari , Sekine Shigeki , Okita Natsuko , Mano Hiroyuki , Nishikawa Hiroyoshi , Nakamura Kenichi , Yonemori Kan
Published: December 2023

Supplementary Figure S6: Immune responses after nivolumab treatment.
Supplementary Table S3 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
Authors: Conte Benedetta , Boni Luca , Bisagni Giancarlo , Durando Antonio , Sanna Giovanni , Gori Stefania , Garrone Ornella , Tamberi Stefano , De Placido Sabino , Schettini Francesco , Pazzola Antonio , Ponzone Riccardo , Montemurro Filippo , Lunardi Gianluigi , Notaro Rosario , De Angioletti Maria , Turletti Anna , Mansutti Mauro , Puglisi Fabio , Frassoldati Antonio , Porpiglia Mauro , Fabi Alessandra , Generali Daniele , Scognamiglio Giovanni , Rossi Maura , Brasó-Maristany Fara , Prat Aleix , Cardinali Barbara , Piccioli Patrizia , Serra Martina , Lastraioli Sonia , Bighin Claudia , Poggio Francesca , Lambertini Matteo , Del Mastro Lucia
Published: December 2023

Patients’ characteristics main and SNPs cohorts GIM5
Supplementary Figure S1 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
Authors: Okuma Hitomi S. , Watanabe Keisuke , Tsuchihashi Kenji , Machida Ryunosuke , Sadachi Ryo , Hirakawa Akihiro , Ariyama Hiroshi , Kanai Masashi , Kamikura Masahisa , Anjo Kenta , Hiramitsu Akari , Sekine Shigeki , Okita Natsuko , Mano Hiroyuki , Nishikawa Hiroyoshi , Nakamura Kenichi , Yonemori Kan
Published: December 2023

Supplementary Figure S1: Translation Research biomarker analysis procedure
Supplementary Table S12 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
Authors: Conte Benedetta , Boni Luca , Bisagni Giancarlo , Durando Antonio , Sanna Giovanni , Gori Stefania , Garrone Ornella , Tamberi Stefano , De Placido Sabino , Schettini Francesco , Pazzola Antonio , Ponzone Riccardo , Montemurro Filippo , Lunardi Gianluigi , Notaro Rosario , De Angioletti Maria , Turletti Anna , Mansutti Mauro , Puglisi Fabio , Frassoldati Antonio , Porpiglia Mauro , Fabi Alessandra , Generali Daniele , Scognamiglio Giovanni , Rossi Maura , Brasó-Maristany Fara , Prat Aleix , Cardinali Barbara , Piccioli Patrizia , Serra Martina , Lastraioli Sonia , Bighin Claudia , Poggio Francesca , Lambertini Matteo , Del Mastro Lucia
Published: December 2023

Univariate analyses for skeletal and cardiovascular events
Supplementary Table S5 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Authors: Marino-Enriquez Adrian , Novotny Jan Philipp , Gulhan Doga C. , Klooster Isabella , Tran Antuan V. , Kasbo Macy , Lundberg Meijun Z. , Ou Wen-Bin , Tao Derrick L. , Pilco-Janeta Daniel F. , Mao Victor Y. , Zenke Frank T. , Leeper Brittaney A. , Gokhale Prafulla C. , Cowley Glenn S. , Baker Laurence H. , Ballman Karla V. , Root David E. , Albers Joachim , Park Peter J. , George Suzanne , Fletcher Jonathan A.
Published: December 2023

Supplementary Table S5:
Molecular features of patient-derived LMS models from Champions Oncology used in in vivo validation studies (five LMS PDX), including clinical and morphological features of LMS tumors from which they were derived.
Supplementary Figure S4 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
Authors: Conte Benedetta , Boni Luca , Bisagni Giancarlo , Durando Antonio , Sanna Giovanni , Gori Stefania , Garrone Ornella , Tamberi Stefano , De Placido Sabino , Schettini Francesco , Pazzola Antonio , Ponzone Riccardo , Montemurro Filippo , Lunardi Gianluigi , Notaro Rosario , De Angioletti Maria , Turletti Anna , Mansutti Mauro , Puglisi Fabio , Frassoldati Antonio , Porpiglia Mauro , Fabi Alessandra , Generali Daniele , Scognamiglio Giovanni , Rossi Maura , Brasó-Maristany Fara , Prat Aleix , Cardinali Barbara , Piccioli Patrizia , Serra Martina , Lastraioli Sonia , Bighin Claudia , Poggio Francesca , Lambertini Matteo , Del Mastro Lucia
Published: December 2023

Figure S4. Cumulative incidence of breast cancer metastasis and breast death in the GIM4 trial (a) and GIM5 study (b).
Table S6 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Authors: He MinKe , Huang YeXing , Du ZeFeng , Lai ZhiCheng , Ouyang Hanyue , Shen JingXian , Wen DongSheng , Li QiJiong , Zhang YaoJun , Wei Wei , Chen MinShan , Xu Li , Kan Anna , Shi Ming
Published: December 2023

Differential expression genes across clusters in the validation cohort.
Supplementary Figure S3 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Authors: Marino-Enriquez Adrian , Novotny Jan Philipp , Gulhan Doga C. , Klooster Isabella , Tran Antuan V. , Kasbo Macy , Lundberg Meijun Z. , Ou Wen-Bin , Tao Derrick L. , Pilco-Janeta Daniel F. , Mao Victor Y. , Zenke Frank T. , Leeper Brittaney A. , Gokhale Prafulla C. , Cowley Glenn S. , Baker Laurence H. , Ballman Karla V. , Root David E. , Albers Joachim , Park Peter J. , George Suzanne , Fletcher Jonathan A.
Published: December 2023

Supplementary Figure S3:
Mutated genes, fraction and counts of non-structural mutations in each gene (right) in clinical samples
from 251 LMS tumors sequenced with OncoPanel. A. Alterations in TP53, RB1 and ATRX were
detected in 73%, 73% and 31% of LMS, respectively, including single copy deletions and low amplitude
gains; B. Alterations in genes mutated in >4% of samples, excluding single copy deletions and low
amplitude gains. Deleterious mutations impacting BRCA2 or BRCA1 were demonstrated in 49% of LMS
and were most often heterozygous deletions, whereas 8% of LMS had identifiable BRCA1/BRCA2
intragenic mutations or homozygous deletions. As with other targeted NGS platforms, these findings
underestimate the true frequency of TP53 and RB1 mutations, given challenges detecting inactivating
structural variants, particularly in large genes such as RB1.
Table S4 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Authors: He MinKe , Huang YeXing , Du ZeFeng , Lai ZhiCheng , Ouyang Hanyue , Shen JingXian , Wen DongSheng , Li QiJiong , Zhang YaoJun , Wei Wei , Chen MinShan , Xu Li , Kan Anna , Shi Ming
Published: December 2023

Clinical information of patients in the exploratory biomarker analysis.
Table S2 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Authors: He MinKe , Huang YeXing , Du ZeFeng , Lai ZhiCheng , Ouyang Hanyue , Shen JingXian , Wen DongSheng , Li QiJiong , Zhang YaoJun , Wei Wei , Chen MinShan , Xu Li , Kan Anna , Shi Ming
Published: December 2023

Treatment Administration
Table S1 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Authors: He MinKe , Huang YeXing , Du ZeFeng , Lai ZhiCheng , Ouyang Hanyue , Shen JingXian , Wen DongSheng , Li QiJiong , Zhang YaoJun , Wei Wei , Chen MinShan , Xu Li , Kan Anna , Shi Ming
Published: December 2023

Representativeness of Study Participants
Supplement 2 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Authors: He MinKe , Huang YeXing , Du ZeFeng , Lai ZhiCheng , Ouyang Hanyue , Shen JingXian , Wen DongSheng , Li QiJiong , Zhang YaoJun , Wei Wei , Chen MinShan , Xu Li , Kan Anna , Shi Ming
Published: December 2023

eMethods
Supplement 1 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Authors: He MinKe , Huang YeXing , Du ZeFeng , Lai ZhiCheng , Ouyang Hanyue , Shen JingXian , Wen DongSheng , Li QiJiong , Zhang YaoJun , Wei Wei , Chen MinShan , Xu Li , Kan Anna , Shi Ming
Published: December 2023

Study Protocol
Supplementary Table S2 from CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Authors: Huang Huanhuan , Yao Yao , Shen Lesang , Jiang Jingxin , Zhang Ting , Xiong Jia , Li Jiaxin , Sun Shanshan , Zheng Siwei , Jia Fang , Zhou Jun , Yu Xiuyan , Chen Wuzhen , Shen Jun , Xia Wenjie , Shao Xuan , Wang Qingqing , Huang Jian , Ni Chao
Published: December 2023

Table. S2. Annotation of the 92 Olink biomarkers studied herein.
Supplementary Table S1 from CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Authors: Huang Huanhuan , Yao Yao , Shen Lesang , Jiang Jingxin , Zhang Ting , Xiong Jia , Li Jiaxin , Sun Shanshan , Zheng Siwei , Jia Fang , Zhou Jun , Yu Xiuyan , Chen Wuzhen , Shen Jun , Xia Wenjie , Shao Xuan , Wang Qingqing , Huang Jian , Ni Chao
Published: December 2023

Table. S1. List of antibodies used in this study.
Figure S7 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Authors: He MinKe , Huang YeXing , Du ZeFeng , Lai ZhiCheng , Ouyang Hanyue , Shen JingXian , Wen DongSheng , Li QiJiong , Zhang YaoJun , Wei Wei , Chen MinShan , Xu Li , Kan Anna , Shi Ming
Published: December 2023

Representative images of patient six.
Supplementary Figure S8 from CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Authors: Huang Huanhuan , Yao Yao , Shen Lesang , Jiang Jingxin , Zhang Ting , Xiong Jia , Li Jiaxin , Sun Shanshan , Zheng Siwei , Jia Fang , Zhou Jun , Yu Xiuyan , Chen Wuzhen , Shen Jun , Xia Wenjie , Shao Xuan , Wang Qingqing , Huang Jian , Ni Chao
Published: December 2023

Fig. S8. Depletion of B cells within the LNs of mice by anti-CD20 antibody injection.
Supplementary Figure S6 from CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Authors: Huang Huanhuan , Yao Yao , Shen Lesang , Jiang Jingxin , Zhang Ting , Xiong Jia , Li Jiaxin , Sun Shanshan , Zheng Siwei , Jia Fang , Zhou Jun , Yu Xiuyan , Chen Wuzhen , Shen Jun , Xia Wenjie , Shao Xuan , Wang Qingqing , Huang Jian , Ni Chao
Published: December 2023

Fig. S6. CD24hiCD27+ Bregs induce the drug resistance of BC cells by secreting IL-6 and TNF-α.
Figure S3 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Authors: He MinKe , Huang YeXing , Du ZeFeng , Lai ZhiCheng , Ouyang Hanyue , Shen JingXian , Wen DongSheng , Li QiJiong , Zhang YaoJun , Wei Wei , Chen MinShan , Xu Li , Kan Anna , Shi Ming
Published: December 2023

Representative images of patient two.
Supplementary Figure S5 from CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Authors: Huang Huanhuan , Yao Yao , Shen Lesang , Jiang Jingxin , Zhang Ting , Xiong Jia , Li Jiaxin , Sun Shanshan , Zheng Siwei , Jia Fang , Zhou Jun , Yu Xiuyan , Chen Wuzhen , Shen Jun , Xia Wenjie , Shao Xuan , Wang Qingqing , Huang Jian , Ni Chao
Published: December 2023

Fig. S5. Direct cell-cell contact between BC cells and CD24hiCD27+ Bregs endows BC cells with stronger stemness and drug resistance.
Figure S2 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Authors: He MinKe , Huang YeXing , Du ZeFeng , Lai ZhiCheng , Ouyang Hanyue , Shen JingXian , Wen DongSheng , Li QiJiong , Zhang YaoJun , Wei Wei , Chen MinShan , Xu Li , Kan Anna , Shi Ming
Published: December 2023

Representative images of patient one.
Supplementary Figure S3 from CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Authors: Huang Huanhuan , Yao Yao , Shen Lesang , Jiang Jingxin , Zhang Ting , Xiong Jia , Li Jiaxin , Sun Shanshan , Zheng Siwei , Jia Fang , Zhou Jun , Yu Xiuyan , Chen Wuzhen , Shen Jun , Xia Wenjie , Shao Xuan , Wang Qingqing , Huang Jian , Ni Chao
Published: December 2023

Fig. S3. CD24hiCD27+ Bregs induce epithelial-mesenchymal transition and stemness of BC cells.
Supplementary Figure S2 from CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Authors: Huang Huanhuan , Yao Yao , Shen Lesang , Jiang Jingxin , Zhang Ting , Xiong Jia , Li Jiaxin , Sun Shanshan , Zheng Siwei , Jia Fang , Zhou Jun , Yu Xiuyan , Chen Wuzhen , Shen Jun , Xia Wenjie , Shao Xuan , Wang Qingqing , Huang Jian , Ni Chao
Published: December 2023

Fig. S2. Comparison of CD24hiCD27+ Bregs from peripheral blood and LNs.
Supplementary Figure S11 from CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Authors: Huang Huanhuan , Yao Yao , Shen Lesang , Jiang Jingxin , Zhang Ting , Xiong Jia , Li Jiaxin , Sun Shanshan , Zheng Siwei , Jia Fang , Zhou Jun , Yu Xiuyan , Chen Wuzhen , Shen Jun , Xia Wenjie , Shao Xuan , Wang Qingqing , Huang Jian , Ni Chao
Published: December 2023

Fig. S11. Anti-PD-L1 treatment attenuates the activation of B cells and improves the treatment response rate of mLNs.
Data from Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma
Authors: Zhao Tiansuo , Jiang Tingting , Li Xiaojia , Chang Shaofei , Sun Qihui , Kong Fanyang , Kong Xiangyu , Wei Fang , He Jie , Hao Jihui , Xie Keping
Published: December 2023

AbstractPurpose:
Stromal fibrosis limits nutritional supply and disarrays metabolism in pancreatic cancer (PDA, pancreatic ductal adenocarcinoma). Understanding of the molecular basis underlying metabolic cues would improve PDA management. The current study determined the interaction between glucose-regulated proteins 78 (GRP78) and hypoxia-inducible factor 1α (HIF-1α) and its mechanistic roles underlying PDA response to oxygen and glucose restrains.
Experimental Design:
Gene expression and its association with clinicopathologic characteristics of patients with PDA and mouse models were analyzed using IHC. Protein expression and their regulation were measured by Western blot and immunoprecipitation analyses. Protein interactions were determined using gain- and loss-of-function assays and molecular methods, including chromatin immunoprecipitation, co-immunoprecipitation, and dual luciferase reporter.
Results:
There was concomitant overexpression of both GRP78 and HIF-1α in human and mouse PDA tissues and cells. Glucose deprivation increased the expression of GRP78 and HIF-1α, particularly colocalization in nucleus. Induction of HIF-1α expression by glucose deprivation in PDA cells depended on the expression of and its own interaction with GRP78. Mechanistically, increased expression of both HIF-1α and LDHA under glucose deprivation was caused by the direct binding of GRP78 and HIF-1α protein complexes to the promoters of HIF-1α and LDHA genes and transactivation of their transcriptional activity.
Conclusions:
Protein complex of GRP78 and HIF-1α directly binds to HIF-1α own promoter and LDHA promoter, enhances the transcription of both HIF-1α and LDHA, whereas glucose deprivation increases GRP78 expression and further enhances HIF-1α and LDHA transcription. Therefore, crosstalk and integration of hypoxia- and hypoglycemia-responsive signaling critically impact PDA metabolic reprogramming and therapeutic resistance.
Data from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Authors: Marino-Enriquez Adrian , Novotny Jan Philipp , Gulhan Doga C. , Klooster Isabella , Tran Antuan V. , Kasbo Macy , Lundberg Meijun Z. , Ou Wen-Bin , Tao Derrick L. , Pilco-Janeta Daniel F. , Mao Victor Y. , Zenke Frank T. , Leeper Brittaney A. , Gokhale Prafulla C. , Cowley Glenn S. , Baker Laurence H. , Ballman Karla V. , Root David E. , Albers Joachim , Park Peter J. , George Suzanne , Fletcher Jonathan A.
Published: December 2023

AbstractPurpose:
Leiomyosarcoma (LMS) is an aggressive sarcoma for which standard chemotherapies achieve response rates under 30%. There are no effective targeted therapies against LMS. Most LMS are characterized by chromosomal instability (CIN), resulting in part from TP53 and RB1 co-inactivation and DNA damage repair defects. We sought to identify therapeutic targets that could exacerbate intrinsic CIN and DNA damage in LMS, inducing lethal genotoxicity.
Experimental Design:
We performed clinical targeted sequencing in 287 LMS and genome-wide loss-of-function screens in 3 patient-derived LMS cell lines, to identify LMS-specific dependencies. We validated candidate targets by biochemical and cell-response assays in vitro and in seven mouse models.
Results:
Clinical targeted sequencing revealed a high burden of somatic copy-number alterations (median fraction of the genome altered =0.62) and demonstrated homologous recombination deficiency signatures in 35% of LMS. Genome-wide short hairpin RNA screens demonstrated PRKDC (DNA-PKcs) and RPA2 essentiality, consistent with compensatory nonhomologous end joining (NHEJ) hyper-dependence. DNA-PK inhibitor combinations with unconventionally low-dose doxorubicin had synergistic activity in LMS in vitro models. Combination therapy with peposertib and low-dose doxorubicin (standard or liposomal formulations) inhibited growth of 5 of 7 LMS mouse models without toxicity.
Conclusions:
Combinations of DNA-PK inhibitors with unconventionally low, sensitizing, doxorubicin dosing showed synergistic effects in LMS in vitro and in vivo models, without discernable toxicity. These findings underscore the relevance of DNA damage repair alterations in LMS pathogenesis and identify dependence on NHEJ as a clinically actionable vulnerability in LMS.
Data from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Authors: He MinKe , Huang YeXing , Du ZeFeng , Lai ZhiCheng , Ouyang Hanyue , Shen JingXian , Wen DongSheng , Li QiJiong , Zhang YaoJun , Wei Wei , Chen MinShan , Xu Li , Kan Anna , Shi Ming
Published: December 2023

AbstractPurpose:
To investigate the efficacy, safety, and biomarkers of systemic chemotherapy with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) in combination with lenvatinib and toripalimab as the first-line treatment for advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis.
Patients and Methods:
In this biomolecular exploratory, phase II trial, eligible patients underwent the triple combination therapy of lenvatinib, toripalimab, plus FOLFOX chemotherapy. Primary endpoint was progression-free survival (PFS) rate at 6 months by RECIST v1.1. Single-nucleus RNA sequencing (snRNA-seq) of tumor biopsy samples was performed for exploratory biomarker analyses.
Results:
Between November 19, 2019, and July 4, 2021, 30 patients were enrolled. The primary endpoint was a 6-month PFS rate of 66.7%, with a median PFS of 9.73 months [95% confidence interval (CI), 2.89–16.58]. The median overall survival (OS) was 14.63 months (95% CI, 11.77–17.50), with an objective response rate of 43.3%. Twenty-four (80.0%) patients exhibited high-risk features, among whom the median OS and PFS were 13.7 months (95% CI, 9.24–18.16) and 8.3 months (95% CI, 3.02–13.58), respectively. The most common adverse events were neutropenia, and increased aspartate aminotransferase and alanine aminotransferase levels. Exploratory analyses of snRNA-seq profiles suggested that patients with higher abundance of tumor-infiltrating immune cells were more likely to benefit from this combination. In addition, two subtypes of hepatocytes (AKR1C2+ and CFHR4+ malignant hepatocytes) were associated with reduced clinical benefits.
Conclusions:
FOLFOX chemotherapy in combination with lenvatinib and toripalimab showed promising antitumor activity with manageable toxicities in advanced HCC with extrahepatic metastasis. AKR1C2+ and CFHR4+ hepatocyte subtypes may be predictive biomarkers of resistance to the combination therapy.
Supplementary Table S3 from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
Authors: Schwarzer Adrian , Oliveira Matheus , Kleppa Marc-Jens , Slattery Scott D. , Anantha Andy , Cooper Alan , Hannink Mark , Schambach Axel , Dörrie Anneke , Kotlyarov Alexey , Gaestel Matthias , Hembrough Todd , Levine Jedd , Luther Michael , Stocum Michael , Stiles Linsey , Weinstock David M. , Liesa Marc , Kostura Matthew J.
Published: December 2023

Biomarker Identification based on cell line screening data results
Supplementary Table S2 from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
Authors: Schwarzer Adrian , Oliveira Matheus , Kleppa Marc-Jens , Slattery Scott D. , Anantha Andy , Cooper Alan , Hannink Mark , Schambach Axel , Dörrie Anneke , Kotlyarov Alexey , Gaestel Matthias , Hembrough Todd , Levine Jedd , Luther Michael , Stocum Michael , Stiles Linsey , Weinstock David M. , Liesa Marc , Kostura Matthew J.
Published: December 2023

Results of screening DLBCL cell lines with compound
Supplementary Table S1 from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
Authors: Schwarzer Adrian , Oliveira Matheus , Kleppa Marc-Jens , Slattery Scott D. , Anantha Andy , Cooper Alan , Hannink Mark , Schambach Axel , Dörrie Anneke , Kotlyarov Alexey , Gaestel Matthias , Hembrough Todd , Levine Jedd , Luther Michael , Stocum Michael , Stiles Linsey , Weinstock David M. , Liesa Marc , Kostura Matthew J.
Published: December 2023

Results of Cell line screening data
Supplementary Vignette 3 from Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology
Authors: Rosenthal Jacob , Carelli Ryan , Omar Mohamed , Brundage David , Halbert Ella , Nyman Jackson , Hari Surya N. , Van Allen Eliezer M. , Marchionni Luigi , Umeton Renato , Loda Massimo
Published: December 2023

In this vignette, we demonstrate a practical example of a complete PathML workflow for analyzing immunofluorescence images
Supplementary Table 1 from Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology
Authors: Rosenthal Jacob , Carelli Ryan , Omar Mohamed , Brundage David , Halbert Ella , Nyman Jackson , Hari Surya N. , Van Allen Eliezer M. , Marchionni Luigi , Umeton Renato , Loda Massimo
Published: December 2023

Table S1 lists the file formats supported by each of PathML's three backends
Table S1 from Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer
Authors: Malhi Vikram , Agarwal Priya , Gates Mary R. , Liu Lichuan , Wang Jianshuang , De Bruyn Tom , Lam Scott , Eng-Wong Jennifer , Perez-Moreno Pablo , Chen Ya-Chi , Yu Jiajie
Published: December 2023

Representativeness of study population
FIGURE 3 from Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer
Authors: Malhi Vikram , Agarwal Priya , Gates Mary R. , Liu Lichuan , Wang Jianshuang , De Bruyn Tom , Lam Scott , Eng-Wong Jennifer , Perez-Moreno Pablo , Chen Ya-Chi , Yu Jiajie
Published: December 2023

Comparison of dose-normalized giredestrant steady-state exposure between fasted and fed patients in single-agent dose-escalation and -expansion cohorts. A, Cmax. B, AUC0–24h. Pharmacokinetic parameters were dose normalized by the dose received at the time of pharmacokinetic sampling—AUC0–24h or Cmax/Dose. The solid line in the center represents the median, the solid line at the bottom is the 25th percentile (Q1), the solid line at the top is the 75th percentile (Q3), the boxes indicate the interquartile range (IQR; Q1–Q3), and the whiskers represent 1.5*IQR.
Tem indígena aqui: reflexões acerca do protagonismo indígena na história em quadrinho da revista almanaque tem cientista aqui
Authors: Champi Paola , Chohfi Júlia Melo , Martins Sarah Marion
Published: December 2023

Partindo da base teórica da Análise do Discurso franco-brasileira e estabelecendo relações com a arte dos quadrinhos com o viés de divulgação científica para o público escolar, são problematizadas as discussões em torno do conhecimento científico e popular através da representatividade e protagonismo indígena. O corpus tomado como objeto de análise é a história em quadrinho "Quantas espécies de peixes existem na bacia amazônica?”, Revista Almanaque Tem Cientista Aqui! de novembro de 2022, da rede Conexões Amazônicas.
Co-infection of Cytauxzoon felis, Mycoplasma haemofelis, and the feline immunodeficiency virus in a domestic cat in Uberlândia, Minas Gerais, Brazil
Authors: Fenelon Ana Carolina Guimarães , Hora Aline Santana da , Silva Karolinna Lourenço da , Oliveira Gustavo Henrique Batista de , Gonçalves Marianne Souto e Silva , Pastor Felipe Martins , Barbosa Fernando Cristino , Siqueira Marco Túlio Santos , Rosalinski-Moraes Fernanda
Published: December 2023

Cytauxzoon felis is a hemoparasite capable of infecting domestic and wild cats. Studies suggest that wild cats are the main reservoirs of the protozoan, and transmission occurs through the bite of an infected tick. Hemotropic mycoplasmas are Gram-negative bacteria responsible for severe hemolytic anemia. The feline immunodeficiency virus (FIV) is a retrovirus capable of generating immunosuppression in the host and persistent infection. The present work describes a case of co infection of Cytauxzoon felis, Mycoplasma haemofelis, and feline immunodeficiency virus (FIV) in a cat. A feline from the rural area was admitted to the Veterinary Hospital of Uberlândia - MG of the Federal University of Uberlândia. Fresh whole blood samples were collected for blood count, enzymatic analysis, DNA extraction, real-time PCR for the detection of Cytauxzoon felis and Mycoplasma haemofelis, and the Point of Care ELISA test for Feline Leukemia Virus (FeLV) antigens and antibodies to feline immunodeficiency virus (FIV). Piroplasms compatible with Cytauxzoon spp. were observed in the smear, and the tests performed were positive for Cytauxzoon felis, Mycoplasma haemofelis, and FIV.
Shared Lexical Items as Triggers of Code Switching
Authors: Wintner Shuly , Shehadi Safaa , Zeira Yuli , Osmelak Doreen , Nov Yuval
Published: December 2023

Why do bilingual speakers code-switch (mix their two languages)? Among the several theories that attempt to explain this natural and ubiquitous phenomenon, the triggering hypothesis relates code-switching to the presence of lexical triggers, specifically cognates and proper names, adjacent to the switch point. We provide a fuller, more nuanced and refined exploration of the triggering hypothesis, based on five large datasets in three language pairs, reflecting both spoken and written bilingual interactions. Our results show that words that are assumed to reside in a mental lexicon shared by both languages indeed trigger code-switching, that the tendency to switch depends on the distance of the trigger from the switch point and on whether the trigger precedes or succeeds the switch, but not on the etymology of the trigger words. We thus provide strong, robust, evidence-based confirmation to several hypotheses on the relationships between lexical triggers and code-switching.
Discover, Explain, Improve: An Automatic Slice Detection Benchmark for Natural Language Processing
Authors: Hua Wenyue , Jin Lifeng , Song Linfeng , Mi Haitao , Zhang Yongfeng , Yu Dong
Published: December 2023

Pretrained natural language processing (NLP) models have achieved high overall performance, but they still make systematic errors. Instead of manual error analysis, research on slice detection models (SDMs), which automatically identify underperforming groups of datapoints, has caught escalated attention in Computer Vision for both understanding model behaviors and providing insights for future model training and designing. However, little research on SDMs and quantitative evaluation of their effectiveness have been conducted on NLP tasks. Our paper fills the gap by proposing a benchmark named “Discover, Explain, Improve (DEIm)” for classification NLP tasks along with a new SDM Edisa. Edisa discovers coherent and underperforming groups of datapoints; DEIm then unites them under human-understandable concepts and provides comprehensive evaluation tasks and corresponding quantitative metrics. The evaluation in DEIm shows that Edisa can accurately select error-prone datapoints with informative semantic features that summarize error patterns. Detecting difficult datapoints directly boosts model performance without tuning any original model parameters, showing that discovered slices are actionable for users.1
Resistance, Transculturation, and Survivance at the Bethany Indian Mission
Authors: Peterson Anna M.
Published: December 2023

This article details an act of Native American protest against the Bethany Indian Mission and the Norwegian Lutheran Church in 1938. In doing so, it engages in and contributes to theoretical discussions of accommodation, transculturation, resistance, and survivance. In 1938 Ho-Chunk in Wisconsin sent a written petition to the Norwegian Lutheran Church in America calling for the removal of the Superintendent of the nearby Bethany Indian Mission. By articulating their grievances in a formal letter sent to Church administrators, the Ho-Chunk invoked a relationship with the Church. The Church did not recognize this mutual relationship with the Ho-Chunk. Instead, Church leaders clearly communicated that its relationship with Native American congregants was tenuous and contingent on numerous factors. The Ho-Chunk signatories contested this unequal relationship, and while the superintendent remained in his position until 1955, their actions prompted the superintendent to both apologize and seek new opportunities to gain the Ho-Chunks’ trust.
Empire of Portland Cement, Concrete Blocks, and Specialty Shingles
Authors: Roldán-Figueroa Rady
Published: December 2023

The article examines the close collaboration between Protestant missionaries and expatriate American construction entrepreneurs in the early 1900s in Puerto Rico. The construction work done by the Czech American architect Antonin Nechodoma (1877–1928), the builder Frank Bond Hatch (1871–1925), and Protestant missionaries represent an instance of this collaboration, which led to the adoption of Portland cement products in the construction of church buildings (Beatriz del Cueto, 2016). Nechodoma’s contribution to the development of a religious architectural language on behalf of Protestant missionaries has been largely neglected. While Nechodoma’s figure has gathered popular attention of late, the aim of this article is to situate changes in the design and construction of ecclesiastic structures associated with Methodism within the larger context of American imperialist expansionism and political change in Puerto Rico. Examined collectively, the new religious buildings of the period 1898–c. 1927 reveal the implantation of a new religious colonialist architectural aesthetic.